NCT05050188View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 24, 2021

Primary Completion Date

September 18, 2021

Study Completion Date

September 25, 2021

Conditions
Erosive Esophagitis
Interventions
DRUG

H008

Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water.

DRUG

H008 placebo

Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water

DRUG

Lansoprazole

Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water

Trial Locations (1)

33136

Syneos Health, Miami

All Listed Sponsors
lead

Jiangsu Carephar Pharmaceutical Co., Ltd.

INDUSTRY